InsiderDB

Lobbying disclosures · Lobbying report

IBRX: second_quarter 2026 lobbying report

A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.

Follow IBRX
Became public
Jul 19, 2026, 4:22 PM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 1:08 AM EST

Why this is connected

Exact legal-name match: ImmunityBio, Inc. (https://www.sec.gov/Archives/edgar/data/1326110/).

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/37f40357-068c-456c-b14d-e8c95a3c9f90/","filing_uuid":"37f40357-068c-456c-b14d-e8c95a3c9f90","filing_type":"2TY","filing_type_display":"2nd Quarter - Termination (No Activity)","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/37f40357-068c-456c-b14d-e8c95a3c9f90/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Alyssa Specht Garcia","dt_posted":"2026-07-19T16:22:09-04:00","termination_date":"2026-06-30","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1747 Pennsylvania Ave NW","registrant_address_2":"Suite 875","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401106285,"url":"https://lda.gov/api/v1/registrants/401106285/","house_registrant_id":null,"name":"CONTINENTAL STRATEGY, LLC","description":"Governmental and Business Consulting","address_1":"1747 Pennsylvania Ave NW","address_2":"Suite 875","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ALYSSA SPECHT GARCIA","contact_telephone":"+1 305-677-2063","dt_updated":"2026-08-06T17:20:09.978161-04:00"},"client":{"id":69499,"url":"https://lda.gov/api/v1/clients/69499/","client_id":69499,"name":"IMMUNITYBIO, INC.","general_description":"Immunotherapy company focused on developing treatments for cancer and infectious diseases.","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-10-01"},"lobbying_activities":[],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

-7.85% IBRX

Adjusted closing prices from Nov 10, 2026 to Nov 12, 2026. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in IBRX

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.